US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sucampo Pharmaceuticals

18.00

+0.0000

Volume:- -

Turnover:- -

Market Cap:839.47M

PE:-5.47

High:18.00

Open:18.00

Low:18.00

Close:18.00

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Sucampo Pharmaceuticals

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.sucampo.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders in the United States, Japan, Switzerland, and internationally. The companys marketed product includes AMITIZA, a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product candidates, which are in clinical development stage comprise Cobiprostone that is in Phase IIa trials for the treatment of oral mucositis, non-erosive reflux, and symptomatic gastroesophageal reflux diseases; RTU-1096, which has completed Phase I trial for treating inflammation/immune-related disorders; and RTU-009 that is in development stage for inflammation/immune-related disorders, as well as CPP-1X/sulindac combination product, which is in phase III clinical trial for the treatment of familial adenomatous polyposis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland. Sucampo Pharmaceuticals, Inc. is a subsidiary of S&R Technology Holdings, LLC.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SCMP/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SCMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCMP\",,,,,undefined,":{"symbol":"SCMP","market":"US","secType":"STK","nameCN":"Sucampo Pharmaceuticals","latestPrice":18,"timestamp":1557518400000,"preClose":18,"halted":4,"volume":0,"delay":0,"floatShares":24340000,"shares":46637000,"eps":-3.29,"marketStatus":"Delisted","change":0,"latestTime":"05-10 16:00:00 EDT","open":18,"high":18,"low":18,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.29,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1186027200000,"exchange":"NASDAQ","adjPreClose":18,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCMP\",,,,,undefined,":{"symbol":"SCMP","floatShares":24340000,"roa":"--","roe":"--","lyrEps":0,"shares":46637000,"dividePrice":0,"high":18,"amplitude":0,"preClose":18,"low":18,"week52Low":9.3,"pbRate":"21.18","week52High":18.75,"institutionHeld":0,"latestPrice":18,"eps":-3.29,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.29,"open":18},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.sucampo.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0385},{"period":"1month","weight":-0.05},{"period":"3month","weight":-0.1008},{"period":"6month","weight":-0.0559},{"period":"1year","weight":0.0817},{"period":"ytd","weight":-0.0672}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research and development of proprietary drugs for the treatment of gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders in the United States, Japan, Switzerland, and internationally. The companys marketed product includes AMITIZA, a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product candidates, which are in clinical development stage comprise Cobiprostone that is in Phase IIa trials for the treatment of oral mucositis, non-erosive reflux, and symptomatic gastroesophageal reflux diseases; RTU-1096, which has completed Phase I trial for treating inflammation/immune-related disorders; and RTU-009 that is in development stage for inflammation/immune-related disorders, as well as CPP-1X/sulindac combination product, which is in phase III clinical trial for the treatment of familial adenomatous polyposis. Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland. Sucampo Pharmaceuticals, Inc. is a subsidiary of S&R Technology Holdings, LLC.","exchange":"NASDAQ","name":"Sucampo Pharmaceuticals","nameEN":"Sucampo Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"SCMP\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCMP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-11-01","symbol":"SCMP","fiscalQuarterEnding":"2017/09","expectedEps":0.25,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1509508800000,"reportTimeType":"pre","actualEps":0.27},{"market":"US","date":"2017-08-02","symbol":"SCMP","fiscalQuarterEnding":"2017/06","expectedEps":0.22,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1501646400000,"reportTimeType":"pre","actualEps":0.28},{"market":"US","date":"2017-05-03","symbol":"SCMP","fiscalQuarterEnding":"2017/03","expectedEps":0.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1493784000000,"reportTimeType":"pre","actualEps":0.23},{"market":"US","date":"2017-03-08","symbol":"SCMP","fiscalQuarterEnding":"2016/12","expectedEps":0.49,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1488949200000,"reportTimeType":"pre","actualEps":0.68},{"market":"US","date":"2016-11-09","symbol":"SCMP","fiscalQuarterEnding":"2016/09","expectedEps":0.26,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1478667600000,"reportTimeType":"pre","actualEps":0.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCMP\",market:\"US\",delay:false,,,undefined,":{}}}